A large population-based study supports an increased risk for diabetic ketoacidosis for users of SGLT2 inhibitors compared with DPP-4 inhibitors, although the absolute risk remains low.
Researchers have identified a marked increase in the proportion of children and adolescents who have diabetic ketoacidosis at the point of type 1 diabetes diagnosis during the COVID-19 pandemic.
UK audit data confirm multiple benefits linked to real-world use of flash glucose monitoring including reduced paramedic callouts and hospital admissions for acute diabetes complications.
06-14-2020 | ADA 2020 | Conference coverage | News
Editorial Board member and Endocrinologist, Sanjay Kalra comments on the issues raised by a clinical case involving sodium glucose cotransporter 2 inhibitor therapy alongside a restrictive diet.
Editorial board member John Wilding casts a critical eye over the positive buzz surrounding the potential uses of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes treatment.
medwireNews outlines which medications have so far been tested as adjunct treatments for type 1 diabetes and summarizes the key trial data showing their benefits or otherwise.